Cargando…
A comprehensive evaluation of Hippo pathway silencing in sarcomas
TAZ and YAP are transcriptional coactivators negatively regulated by the Hippo pathway that have emerged as key oncoproteins in several cancers including sarcomas. We hypothesized that loss of expression of the Hippo kinases might be a mechanism of activating TAZ and YAP. By immunohistochemistry, TA...
Autores principales: | Merritt, Nicole M., Fullenkamp, Colleen A., Hall, Sarah L., Qian, Qining, Desai, Chandni, Thomason, Jon, Lambertz, Allyn M., Dupuy, Adam J., Darbro, Benjamin, Tanas, Munir R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114978/ https://www.ncbi.nlm.nih.gov/pubmed/30167083 http://dx.doi.org/10.18632/oncotarget.25824 |
Ejemplares similares
-
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas
por: Desai, Chandni, et al.
Publicado: (2021) -
TAZ and YAP are frequently activated oncoproteins in sarcomas
por: Fullenkamp, Colleen A., et al.
Publicado: (2016) -
A Trp53(fl/fl)Pten(fl/fl) mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging
por: Buchakjian, Marisa R., et al.
Publicado: (2017) -
Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021) -
TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex
por: Merritt, Nicole, et al.
Publicado: (2021)